| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| alda-1 | aldehyde dehydrogenase activator | Preclinical | PubMed Search | NA | 831629 | CHEMBL465952 |
| coenzyme-I | NA | Phase 2 | Integrity | DB00157 | NA | NA |
| CVT-10216 | aldehyde dehydrogenase inhibitor | Phase 1 | guidebook | NA | NA | NA |
| daidzin | antioxidant | Phase 1 | ClinicalTrials | DB02115 | NA | CHEMBL486422 |
| diphenyleneiodonium | nitric oxide synthase inhibitor | Preclinical | PubMed Search | NA | 3101 | CHEMBL365739 |
| disulfiram,disulfiram,disulfiram | aldehyde dehydrogenase inhibitor,DNA methyltransferase inhibitor,TRPV agonist | Launched,Launched,Launched | FDA Orange Book: disulfiram,FDA Orange Book: disulfiram,FDA Orange Book: disulfiram | DB00822,DB00822,DB00822 | 3117,3117,3117 | CHEMBL964,CHEMBL964,CHEMBL964 |
| guanidine | HSP inhibitor | Launched | FDA Orange Book: guanidine hydrochloride | DB00536 | NA | CHEMBL821 |
| nadide | free radical scavenger | Launched | drugs.com | NA | 5893 | NA |
| thioctic-acid | reducing agent | Launched | ClinicalTrials | DB166 | NA | CHEMBL1234071 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| dexamethasone | glucocorticoid receptor agonist | Launched | FDA Orange Book: dexamethasone | DB01234 | 5702035570203623670230037370740257434046954040469526 | CHEMBL384467 |
| hydrocortisone | glucocorticoid receptor agonist | Launched | FDA Orange Book: hydrocortisone | DB00741 | 5702068570206966024425320346450061452369421457543640 | CHEMBL389621 |
Manual assertion inferred from sequence similarity toi
; Peripheral membrane protein By similarityManual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion inferred from sequence similarity toi
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
; Peripheral membrane protein By similarityManual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
6 PublicationsManual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| L-glutamic-acid | glutamate receptor agonist | Launched | FDA | DB00142 | NA | CHEMBL575060 |
| L-leucine | NA | Phase 3 | ClinicalTrials | DB00149 | NA | CHEMBL291962 |
| MC-1 | NA | Phase 3 | ClinicalTrials | DB00114 | NA | CHEMBL82202 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| AT-406 | IAP antagonist | Phase 1 | ClinicalTrials | NA | NA | CHEMBL2158051 |
| AZD5582 | XIAP inhibitor | Preclinical | PubMed Search | NA | NA | CHEMBL3108827 |
| birinapant | XIAP inhibitor | Phase 2 | ClinicalTrials | DB11782 | NA | CHEMBL3039522 |
| GDC-0152 | XIAP inhibitor | Phase 1 | ClinicalTrials | DB12380 | NA | CHEMBL2063869 |
| SM-164 | XIAP inhibitor | Preclinical | PubMed Search | NA | NA | CHEMBL1774154 |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA,NA | NA,NA | NA,NA | NA,NA | NA,NA | NA,NA | NA,NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| 5-fluorouracil | thymidylate synthase inhibitor | Launched | drugs.com | DB00544 | NA | CHEMBL185 |
| hyaluronic-acid | NA | Launched | drugs.com | NA | NA | CHEMBL2110674 |
Manual assertion based on experiment ini
<p>Manually curated information which has been propagated from a related experimentally characterized protein.</p> <p><a href="/manual/evidences#ECO:0000250">More...</a></p> Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
1 PublicationManual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| exherin | cadherin antagonist | Phase 2 | ClinicalTrials | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
; Single-pass type I membrane protein Sequence analysisManual assertion inferred from sequence similarity toi
<p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More...</a></p> Manual assertion based on experiment ini
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| aceneuramic-acid | NA | Phase 3 | ClinicalTrials | DB04265 | NA | CHEMBL165084 |
| apoptosis-activator-II | carboxylesterase inhibitor | Preclinical | PubMed Search | NA | 1901244 | CHEMBL375126 |
| avasimibe | ACAT inhibitor | Phase 3 | PubMed | DB06442 | NA | CHEMBL101309 |
| benzoin | NA | Preclinical | PubMed Search | NA | NA | CHEMBL19677 |
| cholic-acid | bile acid | Launched | FDA | DB02659 | 221493 | CHEMBL205596 |
| CI-976 | ACAT inhibitor | Phase 1 | Pharmaprojects | NA | 122327 | CHEMBL22373 |
| oseltamivir-phosphate | neuraminidase inhibitor | Launched | FDA Orange Book: oseltamivir phosphate | DB00198 | NA | CHEMBL1229 |
| probucol | atherogenesis inhibitor | Launched | FDA Orange Book: probucol | DB01599 | 4912 | CHEMBL608 |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| creatine | NA | Launched | drugs.com | DB00148 | NA | CHEMBL283800 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| boceprevir | HCV inhibitor | Launched | FDA Orange Book: boceprevir | NA | NA | CHEMBL1233448 |
| E-64,E-64 | calpain inhibitor,cysteine protease inhibitor | Preclinical,Preclinical | PubMed Search,PubMed Search | NA,NA | NA,NA | CHEMBL374508,CHEMBL374508 |
| LY3000328 | cathepsin inhibitor | Phase 1 | ClinicalTrials | NA | NA | CHEMBL3342553 |
| VBY-825 | cathepsin inhibitor | Preclinical | PubMed Search | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| laquinimod | immunosuppressant | Phase 3 | ClinicalTrials | DB06685 | NA | CHEMBL66092 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| AZD5069 | CC chemokine receptor antagonist | Phase 2 | ClinicalTrials | NA | NA | NA |
| AZD8797 | CC chemokine receptor antagonist | Preclinical | PubMed Search | NA | NA | CHEMBL2349310 |
| danirixin | CC chemokine receptor antagonist | Phase 2 | ClinicalTrials | DB11922 | NA | CHEMBL3039531 |
| indoprofen,indoprofen | cyclooxygenase inhibitor,prostanoid receptor antagonist | Withdrawn,Withdrawn | Wikipedia,Wikipedia | NA,NA | 3718,3718 | CHEMBL264931,CHEMBL264931 |
| navarixin | CC chemokine receptor antagonist | Phase 2 | ClinicalTrials | NA | NA | CHEMBL216981 |
| reparixin | CC chemokine receptor antagonist | Phase 3 | ClinicalTrials | DB12614 | NA | CHEMBL191413 |
| SB-225002 | CC chemokine receptor antagonist | Preclinical | PubMed Search | NA | 3854666 | CHEMBL239767 |
| SRT3190 | CC chemokine receptor antagonist | Preclinical | PubMed Search | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| desidustat | hypoxia inducible factor prolyl hydroxylase inhibitor | Preclinical | PubMed Search | NA | NA | NA |
| FG-2216 | hypoxia inducible factor prolyl hydroxylase inhibitor | Phase 2 | ClinicalTrials | DB08687 | NA | CHEMBL426560 |
| FG-4592 | hypoxia inducible factor prolyl hydroxylase inhibitor | Phase 3 | ClinicalTrials | DB04847 | NA | CHEMBL2338329 |
| MK-8617 | hypoxia inducible factor prolyl hydroxylase inhibitor | Preclinical | PubMed Search | NA | NA | NA |
| molidustat | hypoxia inducible factor inhibitor | Phase 3 | ClinicalTrials | NA | NA | CHEMBL3646118 |
| vadadustat | hypoxia inducible factor prolyl hydroxylase inhibitor | Phase 3 | ClinicalTrials | DB12255 | NA | CHEMBL3646221 |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| methyl-aminolevulinate | oxidizing agent | Launched | FDA Orange Book: methyl aminolevulinate hydrochloride | DB00992 | NA | CHEMBL1096562 |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
; Multi-pass membrane protein Sequence analysisManual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
<p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More...</a></p> Manual assertion based on experiment ini
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
<p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More...</a></p> Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| AS-2034178 | free fatty acid receptor agonist | Preclinical | PubMed Search | NA | NA | NA |
| azilsartan | angiotensin receptor antagonist | Launched | FDA Orange Book: azilsartan kamedoxomil | NA | NA | CHEMBL57242 |
| azilsartan-medoxomil | angiotensin receptor antagonist | Launched | Wikipedia | DB08822 | NA | CHEMBL2028661 |
| balaglitazone,balaglitazone | insulin sensitizer,PPAR receptor partial agonist | Phase 3,Phase 3 | ClinicalTrials,ClinicalTrials | NA,NA | NA,NA | CHEMBL213991,CHEMBL213991 |
| BETP | GLP receptor positive allosteric modulator | Preclinical | PubMed Search | NA | NA | NA |
| ciglitazone | PPAR receptor agonist | Phase 2 | Springer | NA | 2750 | CHEMBL1398683 |
| darglitazone | PPAR receptor antagonist | Phase 2 | PubMed | DB14034 | NA | CHEMBL55624 |
| edaglitazone | PPAR receptor agonist | Phase 2 | Springer | NA | NA | NA |
| exenatide | GLP receptor agonist | Launched | FDA Orange Book: exenatide synthetic | NA | NA | CHEMBL414357 |
| GW-0742 | PPAR receptor agonist | Preclinical | PubMed Search | NA | 9934458 | CHEMBL38508 |
| GW-1929 | PPAR receptor agonist | Preclinical | PubMed Search | NA | 4516886 | CHEMBL434063 |
| GW-501516 | PPAR receptor agonist | Phase 2 | ClinicalTrials | DB05416 | 9803963 | CHEMBL38943 |
| ID-1101 | insulin sensitizer | Phase 1 | Unexpected Source | NA | NA | CHEMBL508094 |
| kuromanin | ribosyl cyclase inhibitor | Preclinical | PubMed Search | NA | NA | CHEMBL257839 |
| liraglutide | GLP receptor agonist | Launched | FDA Orange Book: liraglutide recombinant | NA | NA | CHEMBL4084119 |
| lupanine | sodium channel blocker | Phase 1 | PubMed | NA | 6708718 | CHEMBL459396 |
| metacresol | NA | Launched | drugs.com | DB01776 | NA | CHEMBL298312 |
| metformin | insulin sensitizer | Launched | FDA Orange Book: metformin hydrochloride | DB00331 | 4091 | CHEMBL1431 |
| methazolamide | carbonic anhydrase inhibitor | Launched | FDA Orange Book: methazolamide | DB00703 | 4100 | CHEMBL1335656 |
| mitiglinide | insulin secretagogue | Launched | ClinicalTrials | DB01252 | NA | CHEMBL471498 |
| MSDC-0160 | insulin sensitizer | Phase 2 | ClinicalTrials | NA | NA | NA |
| nateglinide | insulin secretagogue | Launched | FDA Orange Book: nateglinide | DB00731 | 600265311309 | CHEMBL783 |
| NO-ASA | cyclooxygenase inhibitor | Phase 2 | ClinicalTrials | DB12445 | 119032 | CHEMBL374385 |
| pioglitazone,pioglitazone | insulin sensitizer,PPAR receptor agonist | Launched,Launched | FDA Orange Book: pioglitazone hydrochloride,FDA Orange Book: pioglitazone hydrochloride | DB1132,DB1132 | 60560,60560 | CHEMBL595,CHEMBL595 |
| repaglinide | insulin secretagogue | Launched | FDA Orange Book: repaglinide | DB00912 | 65981 | CHEMBL1272 |
| rosiglitazone,rosiglitazone | insulin sensitizer,PPAR receptor agonist | Withdrawn,Withdrawn | Wikipedia,Wikipedia | DB412,DB412 | 77999,77999 | CHEMBL333304,CHEMBL333304 |
| S26948 | PPAR receptor agonist | Preclinical | PubMed Search | NA | NA | NA |
| TAK-875 | insulin secretagogue | Phase 3 | ClinicalTrials | DB12491 | NA | CHEMBL1829174 |
| tesaglitazar,tesaglitazar | insulin sensitizer,PPAR receptor agonist | Phase 3,Phase 3 | ClinicalTrials,ClinicalTrials | DB06536,DB06536 | NA,NA | CHEMBL282686,CHEMBL282686 |
| troglitazone,troglitazone | insulin sensitizer,PPAR receptor agonist | Withdrawn,Withdrawn | Wikipedia,Wikipedia | DB08607,DB08607 | 5591,5591 | CHEMBL48,CHEMBL48 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
<p>Manually curated information which has been propagated from a related experimentally characterized protein.</p> <p><a href="/manual/evidences#ECO:0000250">More...</a></p> Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion based on experiment ini
Manual assertion inferred from sequence similarity toi
1 PublicationManual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
; Single-pass type IV membrane protein Sequence analysisManual assertion inferred from sequence similarity toi
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
<p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More...</a></p> Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| marimastat | matrix metalloprotease inhibitor | Phase 3 | ClinicalTrials | DB00786 | NA | CHEMBL279785 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| AZD5153 | bromodomain inhibitor | Phase 1 | ClinicalTrials | NA | NA | CHEMBL4078100 |
| mivebresib | bromodomain inhibitor | Phase 1 | ClinicalTrials | NA | NA | CHEMBL3987016 |
| TWS-119 | glycogen synthase kinase inhibitor | Preclinical | PubMed Search | NA | 9549289 | CHEMBL405759 |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| FRAX486 | serine/threonine kinase inhibitor | Preclinical | PubMed Search | NA | NA | CHEMBL3609326 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| GSK690693 | AKT inhibitor | Phase 1 | ClinicalTrials | DB12745 | NA | CHEMBL494089 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
<p>Manually curated information which has been inferred by a curator based on his/her scientific knowledge or on the scientific content of an article.</p> <p><a href="/manual/evidences#ECO:0000305">More...</a></p> Manual assertion inferred by curator fromi
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| 2-ethoxybenzoic-acid | analgesic agent | Phase 1 | Pharmaprojects | NA | NA | NA |
| aceclofenac | prostanoid receptor antagonist | Launched | drugs.com | DB06736 | 71771 | CHEMBL93645 |
| acemetacin | cyclooxygenase inhibitor | Launched | Wikipedia | DB13783 | 1981 | CHEMBL189171 |
| alclofenac | cyclooxygenase inhibitor | Launched | drugs.com | DB13167 | NA | CHEMBL94081 |
| alpha-linolenic-acid | omega 3 fatty acid stimulant | Phase 3 | ClinicalTrials | DB00132 | 5280934 | CHEMBL8739 |
| amfenac | cyclooxygenase inhibitor | Launched | drugs.com | NA | NA | CHEMBL25146 |
| aminosalicylate | cyclooxygenase inhibitor | Launched | FDA Orange Book: aminosalicylate sodium | DB00233 | NA | CHEMBL1169 |
| ampiroxicam | cyclooxygenase inhibitor | Launched | drugs.com | NA | 2176 | CHEMBL1566249 |
| amtolmetin-guacil | cyclooxygenase inhibitor | Launched | drugs.com | NA | NA | CHEMBL1766570 |
| apyramide | cyclooxygenase inhibitor | Preclinical | PubMed Search | NA | NA | CHEMBL97562 |
| arundic-acid | astrocyte modulating agent | Phase 2/Phase 3 | ClinicalTrials | DB05343 | NA | CHEMBL3187683 |
| asaraldehyde | cyclooxygenase inhibitor | Preclinical | PubMed Search | NA | NA | CHEMBL1164301 |
| aspirin | cyclooxygenase inhibitor | Launched | ClinicalTrials | DB00945 | 2244 | CHEMBL25 |
| azapropazone | cyclooxygenase inhibitor | Withdrawn | Wikipedia | NA | 26098 | CHEMBL1483341 |
| balsalazide | cyclooxygenase inhibitor | Launched | FDA Orange Book: balsalazide disodium | DB01014 | 6335412 | CHEMBL1201346 |
| bendazac | cyclooxygenase inhibitor | Launched | drugs.com | DB13501 | NA | CHEMBL1089221 |
| bromfenac | cyclooxygenase inhibitor | Withdrawn | Wikipedia | DB00963 | 60726 | CHEMBL1077 |
| butylidenephthalide | cyclooxygenase inhibitor | Phase 1/Phase 2 | ClinicalTrials | NA | NA | CHEMBL249592 |
| carprofen | cyclooxygenase inhibitor | Launched | FDA Orange Book: carprofen | DB821 | 2581 | CHEMBL2171250 |
| celecoxib | cyclooxygenase inhibitor | Launched | FDA Orange Book: celecoxib | DB00482 | 2662 | CHEMBL118 |
| cicloprofen | cyclooxygenase inhibitor | Preclinical | PubMed Search | NA | NA | CHEMBL214122 |
| clonixin | cyclooxygenase inhibitor | Preclinical | PubMed Search | DB09218 | NA | CHEMBL1332971 |
| cryptotanshinone,cryptotanshinone | acetylcholinesterase inhibitor,STAT inhibitor | Preclinical,Preclinical | PubMed Search,PubMed Search | DB15579,DB15579 | NA,NA | CHEMBL187460,CHEMBL187460 |
| curcumin,curcumin,curcumin,curcumin | cyclooxygenase inhibitor,histone acetyltransferase inhibitor,lipoxygenase inhibitor,NFkB pathway inhibitor | Launched,Launched,Launched,Launched | ClinicalTrials,ClinicalTrials,ClinicalTrials,ClinicalTrials | NA,NA,NA,NA | 167600395281767,167600395281767,167600395281767,167600395281767 | CHEMBL14,CHEMBL14,CHEMBL14,CHEMBL14 |
| deracoxib | cyclooxygenase inhibitor | Launched | drugs.com | DB11395 | 3058754 | CHEMBL28636 |
| diclofenac | cyclooxygenase inhibitor | Launched | FDA Orange Book: diclofenac | DB00586 | 5018304 | CHEMBL139 |
| diflunisal | prostanoid receptor antagonist | Launched | FDA Orange Book: diflunisal | DB00861 | 3059 | CHEMBL898 |
| dihomo-gamma-linolenic-acid | prostanoid receptor agonist | Phase 2 | PubMed | DB00154 | NA | CHEMBL465183 |
| doconexent | PPAR receptor agonist | Launched | drugs.com | DB03756 | 445580 | CHEMBL367149 |
| droxicam | cyclooxygenase inhibitor | Launched | Wikipedia | DB09215 | NA | CHEMBL1213420 |
| DUP-697 | cyclooxygenase inhibitor | Phase 1 | PubMed | NA | 3177 | CHEMBL42485 |
| epirizole | cyclooxygenase inhibitor | Launched | drugs.com | DB08991 | 3242 | CHEMBL1411693 |
| etodolac | cyclooxygenase inhibitor | Launched | FDA Orange Book: etodolac | DB749 | 330873707528667528 | CHEMBL1315939 |
| etofenamate | cyclooxygenase inhibitor | Launched | drugs.com | DB08984 | 35375 | CHEMBL1451633 |
| etoricoxib | cyclooxygenase inhibitor | Launched | drugs.com | DB01628 | 123619 | CHEMBL416146 |
| felbinac-ethyl | cyclooxygenase inhibitor | Launched | Springer | NA | NA | CHEMBL1886408 |
| fenbufen | cyclooxygenase inhibitor | Launched | drugs.com | DB08981 | 3335 | CHEMBL277522 |
| fentiazac | cyclooxygenase inhibitor | Launched | drugs.com | DB13217 | 28871 | CHEMBL589092 |
| firocoxib | cyclooxygenase inhibitor | Launched | drugs.com | DB09217 | NA | CHEMBL69998 |
| FK-3311 | cyclooxygenase inhibitor | Phase 2 | Pharmaprojects | NA | NA | NA |
| floctafenine | cyclooxygenase inhibitor | Launched | drugs.com | NA | NA | CHEMBL21575 |
| florifenine | anti-inflammatory agent | Preclinical | PubMed Search | NA | NA | CHEMBL2104893 |
| flufenamic-acid | chloride channel blocker | Preclinical | PubMed Search | DB02266 | 3371 | CHEMBL23588 |
| flurbiprofen-(+/-) | NA | NA | PubMed Search | NA | NA | NA |
| flurbiprofen-(S)-(+) | NA | NA | PubMed Search | NA | NA | NA |
| flurbiprofen-axetil | analgesic agent | Launched | FDA Orange Book: flurbiprofen axetil | NA | NA | NA |
| flurizan | gamma secretase inhibitor | Phase 3 | Wikipedia | DB05289 | NA | CHEMBL190083 |
| fosfosal | phosphodiesterase inhibitor | Launched | Pharmaprojects | NA | 3418 | CHEMBL287275 |
| gamma-linolenic-acid,gamma-linolenic-acid | cyclooxygenase inhibitor,prostanoid receptor agonist | Phase 2,Phase 2 | ClinicalTrials,ClinicalTrials | DB13854,DB13854 | NA,NA | CHEMBL464982,CHEMBL464982 |
| ginsenoside-C-K,ginsenoside-C-K | NFkB pathway inhibitor,nitric oxide synthase inhibitor | Phase 1,Phase 1 | ClinicalTrials,ClinicalTrials | NA,NA | NA,NA | CHEMBL3355096,CHEMBL3355096 |
| honokiol | AKT inhibitor | Phase 3 | ClinicalTrials | NA | 72303 | CHEMBL16901 |
| ibuprofen-(S) | cyclooxygenase inhibitor | Launched | ClinicalTrials | DB09213 | NA | CHEMBL175 |
| ibuprofen-lysine | cyclooxygenase inhibitor | Launched | FDA Orange Book: ibuprofen lysine | DB15 | NA | CHEMBL121141 |
| ibuprofen-piconol | cyclooxygenase inhibitor | Launched | drugs.com | NA | NA | CHEMBL216254 |
| ibuproxam,ibuproxam | cyclooxygenase inhibitor,prostaglandin inhibitor | Launched,Launched | Unexpected Source,Unexpected Source | NA,NA | NA,NA | CHEMBL190266,CHEMBL190266 |
| icosapent | platelet aggregation inhibitor | Launched | FDA Orange Book: icosapent ethyl | DB00159 | 446284 | CHEMBL460026 |
| idazoxan | adrenergic receptor antagonist | Phase 3 | ClinicalTrials | NA | NA | CHEMBL1316 |
| iguratimod,iguratimod | cyclooxygenase inhibitor,NFkB pathway inhibitor | Launched,Launched | ClinicalTrials,ClinicalTrials | DB12233,DB12233 | NA,NA | CHEMBL2107455,CHEMBL2107455 |
| indobufen,indobufen | cyclooxygenase inhibitor,platelet aggregation inhibitor | Launched,Launched | drugs.com,drugs.com | NA,NA | NA,NA | CHEMBL1765292,CHEMBL1765292 |
| indomethacin | cyclooxygenase inhibitor | Launched | FDA Orange Book: indomethacin | DB00328 | NA | CHEMBL6 |
| indoprofen,indoprofen | cyclooxygenase inhibitor,prostanoid receptor antagonist | Withdrawn,Withdrawn | Wikipedia,Wikipedia | NA,NA | 3718,3718 | CHEMBL264931,CHEMBL264931 |
| isoxicam | cyclooxygenase inhibitor | Withdrawn | Wikipedia | DB08942 | 54677972 | CHEMBL53292 |
| ketoprofen | cyclooxygenase inhibitor | Launched | FDA Orange Book: ketoprofen | DB19 | 3825 | CHEMBL372052 |
| ketorolac | cyclooxygenase inhibitor | Launched | FDA Orange Book: ketorolac tromethamine | DB465 | 3826 | CHEMBL469 |
| licofelone,licofelone | cyclooxygenase inhibitor,lipoxygenase inhibitor | Phase 3,Phase 3 | Wikipedia,Wikipedia | DB04725,DB04725 | NA,NA | CHEMBL300982,CHEMBL300982 |
| lornoxicam | cyclooxygenase inhibitor | Launched | drugs.com | DB06725 | NA | CHEMBL1569487 |
| loxoprofen,loxoprofen | cyclooxygenase inhibitor,prostanoid receptor antagonist | Launched,Launched | drugs.com,drugs.com | NA,NA | 23663407,23663407 | CHEMBL19299,CHEMBL19299 |
| lumiracoxib | cyclooxygenase inhibitor | Withdrawn | Wikipedia | DB01283 | NA | CHEMBL404108 |
| meclofenamic-acid,meclofenamic-acid | cyclooxygenase inhibitor,prostanoid receptor antagonist | Launched,Launched | FDA Orange Book: meclofenamate sodium,FDA Orange Book: meclofenamate sodium | DB00939,DB00939 | 23663959,23663959 | CHEMBL509,CHEMBL509 |
| mefenamic-acid | cyclooxygenase inhibitor | Launched | FDA Orange Book: mefenamic acid | DB00784 | 4044 | CHEMBL686 |
| meloxicam | cyclooxygenase inhibitor | Launched | FDA Orange Book: meloxicam | DB00814 | 10291556 | CHEMBL599 |
| mesalazine,mesalazine,mesalazine | cyclooxygenase inhibitor,lipoxygenase inhibitor,prostanoid receptor antagonist | Launched,Launched,Launched | FDA Orange Book: mesalamine,FDA Orange Book: mesalamine,FDA Orange Book: mesalamine | DB00244,DB00244,DB00244 | 4075,4075,4075 | CHEMBL704,CHEMBL704,CHEMBL704 |
| metoxibutropate | cyclooxygenase inhibitor | Launched | PubMed | NA | NA | NA |
| nabumetone | cyclooxygenase inhibitor | Launched | FDA Orange Book: nabumetone | DB00461 | 4409 | CHEMBL1070 |
| naproxen | cyclooxygenase inhibitor | Launched | FDA Orange Book: naproxen | DB00788 | 13022368105923675324 | CHEMBL154 |
| nepafenac | cyclooxygenase inhibitor | Launched | FDA Orange Book: nepafenac | DB06802 | NA | CHEMBL1021 |
| niflumic-acid | cyclooxygenase inhibitor | Launched | drugs.com | DB04552 | 4488 | CHEMBL63323 |
| nimesulide | cyclooxygenase inhibitor | Launched | drugs.com | DB04743 | 4495 | CHEMBL56367 |
| nitroflurbiprofen | cyclooxygenase inhibitor | Preclinical | PubMed Search | NA | NA | NA |
| NO-ASA | cyclooxygenase inhibitor | Phase 2 | ClinicalTrials | DB12445 | 119032 | CHEMBL374385 |
| olsalazine | cyclooxygenase inhibitor | Launched | FDA Orange Book: olsalazine sodium | DB01250 | NA | CHEMBL425 |
| oxaprozin | cyclooxygenase inhibitor | Launched | FDA Orange Book: oxaprozin | DB00991 | 4614 | CHEMBL1071 |
| paracetamol | cyclooxygenase inhibitor | Launched | FDA Orange Book: acetaminophen | DB00316 | 1983 | CHEMBL112 |
| parecoxib | cyclooxygenase inhibitor | Launched | drugs.com | DB08439 | 119828 | CHEMBL1206690 |
| phenazone | cyclooxygenase inhibitor | Launched | Wikipedia | DB01435 | 220698889 | CHEMBL277474 |
| phenylbutazone,phenylbutazone | cyclooxygenase inhibitor,prostanoid receptor antagonist | Withdrawn,Withdrawn | Wikipedia,Wikipedia | DB00812,DB00812 | 4781,4781 | CHEMBL101,CHEMBL101 |
| piceatannol | SYK inhibitor | Preclinical | PubMed Search | DB08399 | 4813 | CHEMBL69863 |
| piroxicam | cyclooxygenase inhibitor | Launched | FDA Orange Book: piroxicam | DB00554 | 22723678 | CHEMBL527 |
| proglumetacin | cyclooxygenase inhibitor | Launched | drugs.com | NA | NA | CHEMBL215825 |
| propacetamol | cyclooxygenase inhibitor | Launched | drugs.com | DB09288 | NA | CHEMBL1851805 |
| proquazone | cyclooxygenase inhibitor | Launched | Unexpected Source | DB13649 | NA | CHEMBL268501 |
| pterostilbene,pterostilbene | cyclooxygenase inhibitor,PPAR receptor agonist | Phase 2/Phase 3,Phase 2/Phase 3 | ClinicalTrials,ClinicalTrials | NA,NA | 5281727,5281727 | CHEMBL83527,CHEMBL83527 |
| resveratrol,resveratrol | cytochrome P450 inhibitor,SIRT activator | Launched,Launched | drugs.com,drugs.com | DB02709,DB02709 | 445154,445154 | CHEMBL165,CHEMBL165 |
| rofecoxib | cyclooxygenase inhibitor | Withdrawn | Wikipedia | DB00533 | 5090 | CHEMBL122 |
| rutaecarpine | cyclooxygenase inhibitor | Preclinical | PubMed Search | NA | NA | CHEMBL85139 |
| RWJ-67657 | MAP kinase inhibitor | Phase 1 | PubMed | NA | NA | CHEMBL190333 |
| salicylic-acid,salicylic-acid | cyclooxygenase inhibitor,prostanoid receptor antagonist | Launched,Launched | FDA Orange Book: aminosalicylic acid,FDA Orange Book: aminosalicylic acid | DB00936,DB00936 | NA,NA | CHEMBL424,CHEMBL424 |
| sasapyrine | NFkB pathway inhibitor | Launched | drugs.com | DB01399 | NA | CHEMBL154111 |
| SB-239063 | p38 MAPK inhibitor | Preclinical | PubMed Search | NA | 5166 | CHEMBL97162 |
| SC-236 | cyclooxygenase inhibitor | Preclinical | PubMed Search | DB14059 | NA | CHEMBL282093 |
| sulfasalazine | cyclooxygenase inhibitor | Launched | FDA Orange Book: sulfasalazine | DB00795 | 5359476 | CHEMBL421 |
| sulindac | cyclooxygenase inhibitor | Launched | FDA Orange Book: sulindac | DB65 | 154888715488855352624 | CHEMBL1577 |
| suprofen | cyclooxygenase inhibitor | Withdrawn | Wikipedia | DB87 | 5359 | CHEMBL253765 |
| tenoxicam | cyclooxygenase inhibitor | Launched | drugs.com | DB00469 | 54677971 | CHEMBL302795 |
| thioctic-acid | reducing agent | Launched | ClinicalTrials | DB166 | NA | CHEMBL1234071 |
| tiaprofenic-acid | cyclooxygenase inhibitor | Launched | Wikipedia | DB16 | 5468 | CHEMBL1362630 |
| tolmetin | cyclooxygenase inhibitor | Launched | FDA Orange Book: tolmetin sodium | DB00500 | 5509 | CHEMBL1020 |
| trichlormethiazide | chloride channel blocker | Launched | FDA Orange Book: trichlormethiazide | DB121 | NA | CHEMBL154 |
| triflusal,triflusal,triflusal | cyclooxygenase inhibitor,platelet aggregation inhibitor,thromboxane synthase inhibitor | Launched,Launched,Launched | drugs.com,drugs.com,drugs.com | DB08814,DB08814,DB08814 | 9458,9458,9458 | CHEMBL1332032,CHEMBL1332032,CHEMBL1332032 |
| tropesin | cyclooxygenase inhibitor | Launched | docslide | NA | NA | NA |
| tryptanthrin | cyclooxygenase inhibitor | Preclinical | PubMed Search | NA | NA | CHEMBL306946 |
| ufenamate | cyclooxygenase inhibitor | Launched | drugs.com | NA | NA | CHEMBL2105605 |
| valdecoxib | cyclooxygenase inhibitor | Withdrawn | Wikipedia | DB00580 | 119607 | CHEMBL865 |
| vedaprofen | anti-inflammatory agent | Launched | FDA Orange Book: vedaprofen | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
<p>Manually curated information which has been inferred by a curator based on his/her scientific knowledge or on the scientific content of an article.</p> <p><a href="/manual/evidences#ECO:0000305">More...</a></p> Manual assertion inferred by curator fromi
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| ginsenoside-RE | anti-inflammatory agent | Phase 1 | ClinicalTrials | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| brigatinib,brigatinib | ALK tyrosine kinase receptor inhibitor,EGFR inhibitor | Launched,Launched | DailyMed,DailyMed | DB12267,DB12267 | NA,NA | CHEMBL3545311,CHEMBL3545311 |
| crizotinib | ALK tyrosine kinase receptor inhibitor | Launched | FDA Orange Book: crizotinib | DB08865 | 11626560 | CHEMBL601719 |
| entrectinib,entrectinib | ALK tyrosine kinase receptor inhibitor,proto-oncogene tyrosine protein kinase inhibitor | Launched,Launched | ClinicalTrials,ClinicalTrials | DB11986,DB11986 | NA,NA | CHEMBL1983268,CHEMBL1983268 |
| lorlatinib | ALK tyrosine kinase receptor inhibitor | Launched | DailyMed | NA | NA | CHEMBL328683 |
| PF-06463922 | ALK tyrosine kinase receptor inhibitor | Launched | ClinicalTrials | NA | NA | NA |
| repotrectinib | receptor tyrosine protein kinase inhibitor | Phase 1/Phase 2 | ClinicalTrials | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion inferred by curator fromi
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| bosutinib,bosutinib,bosutinib | Abl kinase inhibitor,Bcr-Abl kinase inhibitor,SRC inhibitor | Launched,Launched,Launched | FDA Orange Book: bosutinib monohydrate,FDA Orange Book: bosutinib monohydrate,FDA Orange Book: bosutinib monohydrate | DB06616,DB06616,DB06616 | 5328940,5328940,5328940 | CHEMBL288441,CHEMBL288441,CHEMBL288441 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
<p>Manually curated information for which there is published experimental evidence.</p> <p><a href="/manual/evidences#ECO:0000269">More...</a></p> Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| ONC201,ONC201 | AKT inhibitor,MAP kinase inhibitor | Phase 2,Phase 2 | ClinicalTrials,ClinicalTrials | DB14844,DB14844 | NA,NA | NA,NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| carbimazole | antithyroid agent | Launched | Wikipedia | DB00389 | 31072 | CHEMBL508102 |
| methimazole | antithyroid agent | Launched | FDA Orange Book: methimazole | DB00763 | 1349907 | CHEMBL1515 |
| propylthiouracil | thyroid peroxidase inhibitor | Launched | FDA Orange Book: propylthiouracil | DB00550 | 657298 | CHEMBL1518 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| 2,4-dinitrophenol | ATP synthase inhibitor | Preclinical | PubMed Search | DB04528 | NA | CHEMBL273386 |
| tafamidis-meglumine | transthyretin amyloid inhibitor | Launched | Wikipedia | DB11644 | NA | CHEMBL2103837 |
| tolcapone | catechol O methyltransferase inhibitor | Withdrawn | Wikipedia | DB00323 | 4659569 | CHEMBL1324 |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion based on experiment ini
Manual assertion inferred from sequence similarity toi
; Single-pass type IV membrane protein CuratedManual assertion inferred from sequence similarity toi
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |
| Compound | MoA i | Clinical Status | Resources | DrugBank | PubChem | ChEMBL |
|---|---|---|---|---|---|---|
| NA | NA | NA | NA | NA | NA | NA |